Group 1 - In July 2023, 670 comparable QDII funds were analyzed, with 586 funds (87.46%) showing an increase in net value, while 80 funds experienced a decline, and 4 funds remained flat [1] - 15 QDII funds had a monthly increase exceeding 24%, with the top performers being E Fund Global Healthcare Mixed Fund (QDII) C (USD) at 28.94%, followed closely by other E Fund variants [1] - The E Fund Global Healthcare Mixed Fund (QDII) C (USD) was established on November 15, 2023, while its A share (USD) was launched on January 20, 2020 [1] Group 2 - As of July 31, 2025, the year-to-date returns for the top E Fund variants were 97.18%, 96.71%, 96.05%, and 95.63%, with cumulative net values ranging from 0.1956 to 1.4089 [2] - The fund maintained a positive outlook on the Chinese pharmaceutical industry, particularly focusing on innovative drug companies, and optimized stock selection as of the second quarter [2] - The largest fund by size among the top performers was the GF CSI Hong Kong Innovative Drug ETF, with a scale of 15.9 billion yuan and a July increase of 27.04% [2] Group 3 - The Manulife India Equity Fund (QDII), established on January 30, 2019, reported a year-to-date return of -2.38% and a cumulative net value of 1.5203 yuan as of July 31, 2025 [3] - The fund's investment strategy shifted from strong defensive positions to include more mid-cap companies and sectors like public utilities and new consumption [3] - The top ten holdings of the Manulife India Equity Fund included major companies such as Reliance Industries and HDFC Bank as of the second quarter [3]

Core Insights - 华夏基金（香港） has been focusing on innovative financial products and positioning itself as a differentiated Chinese institution in the market [1][3] - The CEO, 甘添, believes that the new technology revolution is reshaping the financial industry, providing strategic opportunities for asset management institutions in Hong Kong [1][3] - The offshore RMB bond market is expected to experience explosive growth in the next three to five years, with 华夏香港 already taking the lead in this area [1][5] Company Strategy - 华夏香港 has launched several innovative products, including the first RMB-denominated public fund in Hong Kong and the largest offshore RMB money market ETF, which has grown to a scale of 4.97 billion RMB within two years [3][4] - The company has also introduced the first pure Hong Kong stock biotech ETF and the largest ESG broad-based ETF in Asia (excluding Japan), showcasing its commitment to differentiation in the ETF market [4] Market Outlook - 甘添 predicts that the offshore RMB funds pool could reach approximately 5 trillion RMB by 2030, driven by the internationalization of the RMB and the growth of the dim sum bond market [6][8] - The dim sum bond market has seen significant growth, with the market size increasing from 254 billion RMB in 2020 to nearly 1 trillion RMB currently, indicating a strong demand for these bonds [6][7] Investment Trends - The yield on dim sum bonds is currently more attractive compared to domestic bonds, leading to increased interest from domestic investors facing asset allocation challenges [7][8] - Major domestic enterprises are increasingly using dim sum bonds to replace USD-denominated bonds, reflecting a shift in financing strategies [7][8] Regulatory Environment - The Chinese government is actively supporting the internationalization of the RMB, which is expected to enhance the development of the offshore RMB market [6][8] - Recent policy optimizations, such as the cross-border wealth management connect, are facilitating domestic investors' access to offshore RMB assets, providing a stable funding source for the offshore market [8][9]

Core Viewpoint - 华夏基金（香港） is positioning itself as a differentiated Chinese financial institution, focusing on innovative financial products and capitalizing on emerging market opportunities, particularly in the offshore RMB bond market [1][3][7]. Group 1: Company Strategy and Innovation - 华夏基金（香港） has adopted a forward-looking approach, launching several innovative products, including the first RMB-denominated public fund in Hong Kong, which targets investment-grade bonds [3][7]. - The company has successfully launched the largest offshore RMB money market ETF globally, with a scale of 4.97 billion RMB, demonstrating its ability to identify and capitalize on market trends [3][4]. - The firm has also introduced the first pure Hong Kong stock biotechnology ETF, which has gained significant traction among both domestic and international investors [4][5]. Group 2: Market Outlook and Growth Potential - 甘添, CEO of 华夏基金（香港）, predicts explosive growth in the offshore RMB bond market over the next three to five years, with the offshore RMB fund pool expected to reach approximately 5 trillion RMB by 2030 [1][7]. - The point bond market has seen substantial growth, with its scale increasing from 254 billion RMB in 2020 to nearly 1 trillion RMB currently, driven by attractive yields compared to domestic bonds [8][9]. - The company anticipates that the increasing participation of domestic institutions in the offshore RMB market will be fueled by favorable policies and the growing appeal of point bonds [9][10]. Group 3: Regulatory and Market Dynamics - The Chinese government is actively supporting the internationalization of the RMB, which is expected to enhance the development of the offshore RMB market and create a stable liquidity supply channel [7][9]. - Recent policy changes, such as the relaxation of cross-border investment channels, are expected to facilitate domestic investors' access to offshore RMB assets, further boosting market growth [9][10]. - The shift in the Hong Kong stock market's pricing power, with increasing domestic investment, indicates a changing landscape where local investors are becoming more influential [10][11].

Core Viewpoint - 华夏基金（香港） is positioning itself as a differentiated Chinese financial institution, focusing on innovative financial products and capitalizing on emerging market opportunities [1][2]. Group 1: Innovation and Market Positioning - 华夏香港 has adopted a forward-looking approach, launching several first-of-their-kind financial products in the Hong Kong market, including the first RMB-denominated public fund and the largest offshore RMB money market ETF [2][3]. - The company has successfully identified and capitalized on market trends, such as the growth of the offshore RMB bond market, by launching products like the 华夏精选人民币投资级别收益基金 during a period of currency volatility [2][3]. Group 2: Offshore RMB Bond Market - 甘添 predicts explosive growth in the offshore RMB bond market over the next three to five years, with the offshore RMB fund pool expected to reach approximately 5 trillion by 2030 [2][5]. - The point bond market has seen significant growth, with its scale increasing from 2.54 trillion in 2020 to nearly 10 trillion currently, driven by a decrease in RMB financing costs [6][7]. Group 3: Investment Opportunities - The point bond market offers attractive yields compared to domestic bonds, with yields for similar maturity bonds being 30-50 basis points higher than their domestic counterparts [6][7]. - Major domestic enterprises are increasingly participating in the point bond market, with significant issuances from companies like 百度 and 蒙牛乳业, indicating strong market demand [7][8]. Group 4: Market Dynamics and Future Outlook - The influx of domestic capital into the Hong Kong stock market is shifting the pricing power, with local investors now holding a significant portion of shares [8]. - The anticipated introduction of a mechanism allowing mainland investors to directly invest in Hong Kong stocks using offshore RMB is expected to enhance participation and pricing power in the market [8].

Group 1 - The core viewpoint of the report indicates that the construction materials and coal industries performed well during the period, with the Shanghai Composite Index rising by 1.67% and the Shenzhen Component Index increasing by 2.33% [2][9] - In the recent 12 periods, the comprehensive and pharmaceutical industries showed strong performance, suggesting potential investment opportunities in these sectors [9] - Active equity funds focusing on electronics and coal industries also demonstrated superior performance during this period [14] Group 2 - Among various fund types, actively managed stock funds increased by 1.55%, while mixed funds rose by 1.63%, and bond funds saw a slight decline of 0.16% [2] - The average return of convertible bond funds was notably high at 12.46% year-to-date, indicating a strong performance in this category [17] - QDII funds, particularly those focused on Asia-Pacific and emerging markets, led the performance with an increase of 2.56% during the period [19][21]

Core Viewpoint - The ETF performance in the first half of 2025 shows a stark contrast, with the Hong Kong innovative drug ETFs surging over 58%, while the photovoltaic industry ETFs faced a decline of over 11% [2][3]. Group 1: Performance of Innovative Drug ETFs - The top-performing ETFs are dominated by the pharmaceutical sector, particularly focusing on Hong Kong innovative drugs and biotechnology, indicating strong investor interest in the innovative drug field [3]. - The leading ETF, Huatai-PB Hong Kong Innovative Drug ETF, achieved a remarkable increase of 58.77%, with a scale of 7.802 billion [4]. - Other notable ETFs include Yinhua and Wanji's Hong Kong Innovative Drug ETFs, both exceeding 57% growth, showcasing significant capital involvement in the sector [4][5]. Group 2: Performance of Photovoltaic and Traditional Energy ETFs - In stark contrast, the coal and photovoltaic industry ETFs experienced significant declines, with the top loser, Guotai Zhongzheng Coal ETF, dropping by 12.28% [6][7]. - The photovoltaic ETFs collectively faced severe downturns, with all listed ETFs in this category recording declines exceeding 11%, reflecting the industry's adjustment pressures [7][8]. Group 3: Underlying Market Dynamics - The extreme market divergence reflects a sensitive response to changes in industry trends, driven by supportive policies for innovative drugs and the challenges faced by traditional energy and photovoltaic sectors [9]. - Recent policies from various government departments have provided robust support for the innovative drug industry, enhancing its development prospects [9][10]. - Conversely, the photovoltaic sector is grappling with overcapacity and financial losses, with expectations for a prolonged adjustment period before recovery [10]. Group 4: Future Outlook - The innovative drug market in China is projected to have significant growth potential, driven by low per capita medical spending and an aging population [11]. - The Hong Kong innovative drug sector is expected to continue its rapid development, supported by policy initiatives and advancements in research and commercialization [11][12]. - Long-term perspectives suggest that innovative drugs represent a "long slope, thick snow" sector, emphasizing the importance of distinguishing between thematic speculation and value growth [12].

Group 1 - The average net value of QDII funds increased by 13.19% in the first half of the year, with significant performance from Hong Kong innovative drug sector funds, many of which saw net value increases exceeding 40% [1] - The top-performing QDII fund, Huatai-PB Hang Seng Innovation Drug ETF, achieved a remarkable 93.49% increase, followed by several other funds with gains over 50% [1] - QDII products related to European stock markets and gold also performed well, with net value increases surpassing 20% for funds like Huaan Germany DAX ETF and Jiashe Gold [1] Group 2 - Oil-related QDII funds experienced significant volatility in returns this year, with Brent crude oil prices dropping below $60 per barrel in April due to OPEC production increases and weak demand [2] - Following recent geopolitical tensions, international oil prices have rebounded, leading to a recovery in the returns of oil-related QDII funds, with Jiashe Oil seeing a 12.14% increase in net value since June [2] - Other oil-related ETFs, such as the Fuguo S&P Oil and Gas Exploration and Production Select Industry ETF, also reported net value increases exceeding 5% [2]

Core Viewpoint - The QDII funds have shown remarkable performance in the first half of 2025, with equity products achieving net value growth rates close to 90%, driven by strong rebounds in the Hong Kong stock market, particularly in sectors like innovative drugs, new consumption, and technology [1][2]. QDII Fund Performance - As of June 26, 2025, the average net value growth rate of 312 equity QDII funds was 12.5%, with top performers primarily in the innovative drug and biopharmaceutical sectors [3]. - The fund managed by Zhang Wei, Huatai-PB Hong Kong Advantage Selection A, led the market with a net value growth rate of 89.15% [3]. - Other notable funds include Huatai-PB Hang Seng Innovative Drug ETF and GF CSI Hong Kong Innovative Drug ETF, both exceeding 54% growth [3]. Market Drivers - The strong performance of QDII funds is attributed to the robust performance of the Chinese market, particularly the significant rise in stock prices of Hong Kong internet technology companies [3]. - The Chinese macroeconomic landscape has shown signs of stabilization, with no significant negative impacts from tariff policies, and a trend of upward reversal in the fundamentals of the technology sector [3][4]. Investment Opportunities - Looking ahead to the second half of 2025, there are significant investment opportunities in Hong Kong stocks, especially in leading companies within the internet, innovative drugs, and new consumption sectors [5][6]. - The Hong Kong stock market is seen as being in a value recovery phase, with many high-quality companies successfully expanding globally, which has not yet been fully priced in [6]. Sector Focus - The technology sector in Hong Kong is highlighted as a key area for investment, driven by the macroeconomic narrative of asset revaluation and the rise of the Chinese technology industry [7]. - The Hang Seng Technology Index is characterized by low valuations and high growth potential, with expectations of strong earnings growth for its constituent companies [8]. Global Market Insights - There is a positive outlook for the US stock market, particularly in the technology sector, supported by a clearer shift in monetary policy and favorable fiscal signals [8][9]. - Key factors for the US market include anticipated interest rate cuts, easing financial regulations, and a manageable risk environment in the bond market [8][9]. Regional Opportunities - Investment managers are focusing on three main areas for the second half: the US technology sector, gold as a hedge against geopolitical changes and a weakening dollar, and regional opportunities in East and Southeast Asia [9].

Core Viewpoint - The article highlights the strong performance of Hong Kong ETFs in 2025, driven by optimistic market sentiment and significant capital inflows, particularly in technology sectors such as robotics and artificial intelligence [2][7]. Group 1: Hong Kong Market Performance - The Hang Seng Index and Hang Seng Tech Index have shown notable increases of 16.1008% and 15.7185% respectively as of May 30, 2025, indicating a robust start to the year [2]. - The overall positive sentiment in the Hong Kong market is attributed to a favorable global monetary policy environment and China's economic resilience, which enhances the attractiveness of Hong Kong stocks compared to A-shares [7]. Group 2: Understanding Hong Kong ETFs - Hong Kong ETFs are funds that track Hong Kong-listed stocks, allowing investors to gain exposure to the market through a single investment, similar to a "one-click package" of quality stocks [3]. - These ETFs are primarily listed on mainland exchanges, enabling domestic investors to trade them in RMB without needing a Hong Kong stock account, thus lowering entry barriers for investors [3][4]. Group 3: Advantages of Hong Kong ETFs - The cross-border nature of Hong Kong ETFs allows for easier access to the Hong Kong market without the need for additional accounts or foreign exchange quotas, making them suitable for first-time investors [4]. - Unlike the T+1 settlement of most A-shares, some Hong Kong ETFs offer T+0 trading, providing greater flexibility for short-term trading strategies [5]. - The trading costs associated with Hong Kong ETFs are generally lower than direct investments in Hong Kong stocks, as they are exempt from certain fees like stamp duty, enhancing their long-term investment value [6]. Group 4: Current ETF Offerings - A list of current Hong Kong ETFs available for margin trading includes various funds such as Huazhang Hang Seng Internet Technology ETF, GF Hang Seng Consumer ETF, and others, providing diverse investment options for investors [9].